This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
A new analysis from ADVI shows how the federal government routinely neglected to provide oversight of the 340B program. While 99.7% of 340B providers escape scrutiny due to a lack of oversight, the majority of audits that are conducted reveal adverse findings, raising serious concerns.
Researchers investigated Norwegian pharmacists to understand their expertise, and potential knowledge gaps, regarding issues of epilepsy and treatment using antiseizure medication.
A new pilot program announced by FDA Commissioner Dr. Martin Makary would award vouchers that could cut drug reviews to one or two months — but only for products that meet a special criteria.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
AI-Generated Summary This article by infectious diseases pharmacist Aneeka Chavda outlines five key considerations for pharmacists in the treatment of Mycobacterium tuberculosis (TB), particularly drug-sensitive cases. It emphasizes the critical but potentially underdosed role of rifampicin, highlighting research into higher doses that may improve outcomes.
Now that Gilead Sciences has won U.S. regulatory approval for its groundbreaking HIV prevention drug , the company has another hurdle to clear — ensuring the medicine can be accessed in low-income countries where the disease remains a stubborn problem. As far as Gilead is concerned, the groundwork exists to meet that goal. Last October, the drugmaker reached voluntary licensing agreements to eventually make lenacapavir available in 120 mostly low- and lower-middle-income countries.
Researchers developed, pilot-tested, and evaluated the feasibility of a telehealth electronic application that simulated pharmacists’ prescribing of contraceptives to adolescents and young adults.
468
468
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Researchers developed, pilot-tested, and evaluated the feasibility of a telehealth electronic application that simulated pharmacists’ prescribing of contraceptives to adolescents and young adults.
Moderna's mRNA-1345 vaccine gains FDA approval, enhancing protection against RSV for high-risk adults aged 18 to 59, following earlier approvals for older populations.
The United States leads the world in the research and development, manufacturing and access of innovative medicines. Today, more than half of global biopharmaceutical research and development happens in the United States alone. That’s not by accident: America’s innovation ecosystem is the best in the world, thanks to a policy environment that incentivizes innovation and rewards progress, and it supports workers, the economy and our patients.
As regulator prepares to approve lenacapavir in the US, campaigners are urging the manufacturer, Gilead, to make it ‘available and affordable for all who need it’ A drug with the potential to “end the HIV pandemic” will launch in the US this week – as a new study reveals it could be sold for 1,000 times less than its possible price tag. Lenacapavir, given as a twice-yearly injection, can prevent someone from being infected with HIV, according to clinical trial results.
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Amina Abubakar, PharmD, AAHIVP, joined Drug Topics to discuss her career journey as an independent pharmacy owner and the ways in which she’s been able to grow her business.
Amy Duong, PharmD, BCACP, explains pharmacists' critical role in promoting chronic inflammatory demyelinating neuropathy (CIDP) treatment adherence and staying informed about new therapeutic developments.
The staff of two world-class laboratories at the Centers for Disease Control and Prevention that were slated to be closed in a round of cuts announced in April have been informed that their terminations have been canceled. The CDC’s sexually transmitted disease laboratory and its viral hepatitis laboratory were targets of layoffs initiated by the U.S.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Supply chains for a new generation of therapies are complex, costly, and require meticulous management to ensure patient safety and regulatory compliance. AI can transform cell and gene therapy (CGT) orchestration by automating manual processes, improving productivity, enhancing supply chain visibility and improving scalability.
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
In two phase 3 clinical trials, enlicitide decanoate demonstrated clinically significant reductions in low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidemia and familial hypercholesterolemia.
By Max Kopp Diabetes care is entering a new era—yet even in 2025, continuous glucose monitors (CGMs) remain out of reach for millions. Despite a decade of innovation, current CGMs often fail to meet the needs of everyday people with type 2 diabetes, particularly those in under-resourced or underserved communities. High costs, skin invasiveness, and insurance limitations act as real barriers, not just for adoption, but for long-term engagement.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
LONDON — A U.K. health agency reiterated on Thursday that the limited benefits of a pair of new Alzheimer’s drugs do not justify their high prices, meaning the medicines won’t be made available through the National Health Service. The decision by the U.K.’s cost-effectiveness watchdog reflects how health authorities in different parts of the world have taken different approaches with the drugs, which are the first to have shown they can slow the progression of the dis
The U.S. Food and Drug Administration (FDA) has approved Widaplik, a new triple combination medication designed to treat high blood pressure in adults. Widaplik is the first single pill containing three different drugs approved as an initial treatment for hypertension. It’s a huge win for people who would otherwise likely need several different prescriptions to optimize their cardiovascular health.
At the Total Pharmacy Solutions Summit Spring 2025 event, diagnostics experts Jenna Anderson and Amanda Wiley explored community pharmacists’ role in at-home testing.
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, co-chair of the 2025 Oncology Pharmacists Connect (OPC) meeting, discusses what makes the event unique, highlights key sessions, and shares her excitement for the educational and networking opportunities.
This is the online version of our BIO 2025 newsletter. Get more BIO updates directly to your inbox by signing up here , and sign up for our morning biotech news roundup newsletter here. Hello all, I have a fresh double shot of espresso in hand, which I’m sure would please my colleague Ed Silverman , aka Pharmalot. BIO has been busy this year.
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to
NEW YORK — All 17 experts recently dismissed from a government vaccine advisory panel published an essay Monday decrying “destabilizing decisions” made by U.S. Health Secretary Robert F. Kennedy Jr. that could lead to more preventable disease spread. Kennedy last week announced he would “retire” the entire panel that guides U.S. vaccine policy.
The intersection of artificial intelligence and pharmaceutical marketing is creating new waves of innovation. In 2025, AI generated marketing campaigns are no longer experimental. They are being deployed to personalize content, predict engagement, and automate outreach. But is the pharma industry truly ready to embrace these capabilities? Table of Contents What Are AI Generated Marketing Campaigns?
Louisiana opened the investigation upon discovering a CVS text message campaign sent out to patients asking them to advocate against proposed legislation.
Panelists discuss how pharmacists are essential in managing chronic graft-vs-host disease (cGVHD) by addressing challenges like toxicity, financial and logistical barriers, and a lack of awareness, while advocating for patient education, collaboration with health care teams, and ensuring access to necessary therapies.
The Medicare pay bump for doctors that was part of the House version of Republicans’ tax bill was dropped in the Senate’s version, released Monday evening. The provision, which would boost doctors’ payment for treating Medicare patients by tying it to inflation, has long been a top priority for physician groups. For years, doctors have contended with pay cuts from Medicare, which physician groups say have led to the consolidation and closure of medical practices.
126
126
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
341 
Let's personalize your content